Appendix 3B
Released
Released
Announcement PDF
Appendix 3B
New issue announcement
Appendix 3B
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
New issue announcement,
application for quotation of additional securities
and agreement
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05,
01/08/12, 04/03/13
Name of entity
Imagion Biosystems Ltd
ABN
42 616 305 027
We (the entity) give ASX the following information.
Part 1 - All issues
You must complete the relevant sections (attach sheets if there is not enough space).
1
2
3
+Class of +securities issued or to
be issued
Number of +securities issued or
to be issued (if known) or
maximum number which may be
issued
Principal terms of the +securities
(e.g. if options, exercise price and
expiry date; if partly paid
+securities,
the
amount
outstanding and due dates for
+convertible
payment;
if
securities, the conversion price
and dates for conversion)
Fully Paid Ordinary Shares (FPOs)
2,500,000 FPOs
Fully Paid Ordinary Shares (FPOs)
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 1
Appendix 3B
New issue announcement
4
Do the +securities rank equally in
all respects from the +issue date
with an existing +class of quoted
+securities?
The FPOs will rank equally in all respects with
existing FPOs.
If the additional +securities do
not rank equally, please state:
the date from which they do
the extent to which they
participate for the next
dividend, (in the case of a
trust, distribution) or interest
payment
the extent to which they do
not rank equally, other than
in relation to the next
dividend, distribution or
interest payment
5
Issue price or consideration
6
Purpose of the issue
(If issued as consideration for
the acquisition of assets, clearly
identify those assets)
The FPOs are issued as part of consideration
for professional investor relations services.
6a
Is the entity an +eligible entity
that has obtained security holder
approval under rule 7.1A?
YES
AUD 0.02 per FPO
If Yes, complete sections 6b – 6h
in relation to the +securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
6c
Number of +securities issued
without security holder approval
under rule 7.1
2,500,000 FPOs
Number of +securities issued
with security holder approval
under rule 7.1A
N/A
6d
31 May 2019
+ See chapter 19 for defined terms.
Appendix 3B Page 2
04/03/2013
Appendix 3B
New issue announcement
6e
Number of +securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
N/A
6f
Number of +securities issued
under an exception in rule 7.2
N/A
6g
If +securities issued under rule
7.1A, was issue price at least
75% of 15 day VWAP as
calculated under rule 7.1A.3?
Include the +issue date and both
values. Include the source of the
VWAP calculation.
N/A
If +securities were issued under
rule
7.1A
for
non-cash
consideration, state date on
which valuation of consideration
was released to ASX Market
Announcements
N/A
6h
6i
Calculate the entity’s remaining
issue capacity under rule 7.1 and
rule 7.1A – complete Annexure 1
and release to ASX Market
Announcements
ASX Listing Rule 7.1: 63,855,222
ASX Listing Rule 7.1A: 50,533,688
7
+Issue dates
10 December 2019
Note: The issue date may be prescribed by ASX
(refer to the definition of issue date in rule
19.12). For example, the issue date for a pro
rata entitlement issue must comply with the
applicable timetable in Appendix 7A.
Cross reference: item 33 of Appendix 3B.
8
Number
+class
Number
all 508,782,191
and
of
quoted on ASX
(including the +securities in
section 2 if applicable)
+securities
96,706,395
+Class
Fully Paid Ordinary
Shares.
Listed Options IBXO
(exercisable at $0.05
on or before 26
November 2020).
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 3
Appendix 3B
New issue announcement
9
10
Number
+class
and
of all
not quoted on ASX
(including the +securities in
section 2 if applicable)
+securities
Dividend policy (in the case of a
trust, distribution policy) on the
increased capital (interests)
Number
+Class
10,750,000
Performance Rights
Options
5,112,500
Options: (exercisable
at $0.028 on or before
26 November 2020)
3,000,000
Options: (exercisable
at $0.20 on or before
20 June 2020)
34,700,000
2018 Rights Issue
Lead Manager
Options: (exercisable
at $0.06 on or before
27 November 2020)
2,017,553
Employee Options:
(exercisable at various
prices between
$0.0256 at $0.0302
with varying expiry
dates between 22
February 2021 and 6
June 2021)
600,000
Advisory Board
Options: (exercisable
at $0.06, vesting
quarterly over two
years and with varying
expiry dates between
22 August 2024 and 7
October 2024)
N/A
Part 2 - Pro rata issue
11
Is security
required?
holder
approval
N/A
12
Is the issue renounceable or nonrenounceable?
N/A
13
Ratio in which the +securities will
be offered
N/A
+ See chapter 19 for defined terms.
Appendix 3B Page 4
04/03/2013
Appendix 3B
New issue announcement
14
+Class of +securities to which the
15
+Record
16
Will holdings on different
registers (or subregisters) be
aggregated
for
calculating
entitlements?
17
18
offer relates
date
entitlements
to
determine
N/A
N/A
N/A
Policy for deciding entitlements in
relation to fractions
N/A
Names of countries in which the
entity has security holders who
will not be sent new offer
documents
N/A
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing date for receipt
acceptances or renunciations
of
N/A
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 5
Appendix 3B
New issue announcement
20
Names of any underwriters
N/A
21
Amount of any underwriting fee
or commission
22
Names of any brokers to the issue
N/A
N/A
23
Fee or commission payable to the
broker to the issue
N/A
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of security holders
N/A
If the issue is contingent on
security holders’ approval, the
date of the meeting
N/A
Date entitlement and acceptance
form and offer documents will be
sent to persons entitled
N/A
If the entity has issued options,
and the terms entitle option
holders to participate on exercise,
the date on which notices will be
sent to option holders
N/A
28
Date rights trading will begin (if
applicable)
N/A
29
Date rights trading will end (if
applicable)
25
26
27
30
31
N/A
How do security holders sell their
entitlements in full through a
broker?
N/A
How do security holders sell part
of their entitlements through a
broker and accept for the
balance?
N/A
+ See chapter 19 for defined terms.
Appendix 3B Page 6
04/03/2013
Appendix 3B
New issue announcement
32
33
How do security holders dispose
of their entitlements (except by
sale through a broker)?
N/A
+Issue date
N/A
Part 3 - Quotation of securities
You need only complete this section if you are applying for quotation of securities
34
Type of +securities
(tick one)
(a)
+Securities described in Part 1
(b)
All other +securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid,
employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible
securities
Entities that have ticked box 34(a)
Additional securities forming a new class of securities
Tick to indicate you are providing the information or
documents
35
+
+
If the securities are equity securities, the names of the 20 largest holders of the
additional securities, and the number and percentage of additional securities
+
+
held by those holders
36
+
+
If the securities are equity securities, a distribution schedule of the additional
securities setting out the number of holders in the categories
+
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
37
+
A copy of any trust deed for the additional securities
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 7
Appendix 3B
New issue announcement
Entities that have ticked box 34(b)
38
39
40
Number of +securities for which
+quotation is sought
of +securities for which
quotation is sought
+Class
N/A
Do the +securities rank equally in
all respects from the +issue date
with an existing +class of quoted
+securities?
If the additional +securities do not
rank equally, please state:
the date from which they do
the extent to which they
participate for the next
dividend, (in the case of a trust,
distribution)
or
interest
payment
the extent to which they do not
rank equally, other than in
relation to the next dividend,
distribution
or
interest
payment
41
N/A
N/A
Reason for request for quotation
now
Example: In the case of restricted securities, end
of restriction period
(if issued upon conversion of
another +security, clearly identify
that other +security)
42
Number
Number
+Class
N/A
N/A
+class
and
of all
quoted
on
ASX
(including the +securities in clause
38)
+securities
N/A
+ See chapter 19 for defined terms.
Appendix 3B Page 8
04/03/2013
Appendix 3B
New issue announcement
Quotation agreement
1
2
+Quotation of our additional +securities is in ASX’s absolute discretion.
may quote the +securities on any conditions it decides.
ASX
We warrant the following to ASX.
The issue of the +securities to be quoted complies with the law and is
not for an illegal purpose.
There is no reason why those +securities should not be granted
+quotation.
An offer of the +securities for sale within 12 months after their issue
will not require disclosure under section 707(3) or section 1012C(6) of
the Corporations Act.
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able
to give this warranty
Section 724 or section 1016E of the Corporations Act does not apply to
any applications received by us in relation to any +securities to be
quoted and that no-one has any right to return any +securities to be
quoted under sections 737, 738 or 1016F of the Corporations Act at the
time that we request that the +securities be quoted.
If we are a trust, we warrant that no person has the right to return the
+securities to be quoted under section 1019B of the Corporations Act at
the time that we request that the +securities be quoted.
3
We will indemnify ASX to the fullest extent permitted by law in respect of any
claim, action or expense arising from or connected with any breach of the
warranties in this agreement.
4
We give ASX the information and documents required by this form. If any
information or document is not available now, we will give it to ASX before
+quotation of the +securities begins. We acknowledge that ASX is relying on the
information and documents. We warrant that they are (will be) true and
complete.
Sign here:
............................................................
Company Secretary
Print name:
Jovanka Naumoska
Date:10 December 2019
== == == == ==
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 9
Appendix 3B
New issue announcement
Appendix 3B – Annexure 1
Calculation of placement capacity under rule 7.1 and rule
7.1A for eligible entities
Introduced 01/08/12 Amended 04/03/13
Part 1
Rule 7.1 – Issues exceeding 15% of capital
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
Insert number of fully paid +ordinary
securities on issue 12 months before the
+issue date or date of agreement to issue
332,742,824
Add the following:
962,500
FPOs issued on 24 June 2019
(rule 7.2, exception 9- Vesting
of Performance Rights)
31,250
FPOs issued on 30 September
2019 (rule 7.2, exception 9 Vesting of employee
Performance Rights)
187,250
FPOs issued on 4 October
2019(rule 7.2, exception 9 Vesting of employee Options)
•
Number of fully paid +ordinary securities
issued in that 12 month period under an
exception in rule 7.2
•
Number of fully paid +ordinary securities
issued in that 12 month period with
shareholder approval
•
Number of partly paid +ordinary
securities that became fully paid in that
12 month period
Note:
• Include only ordinary securities here –
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
FPOs on issue as at 10
December 2018.
181,412,807 FPOs issued on 26 November
2019 (rule 7.2, exception 1,
exception 2 and 3 – 2019
rights issue, shortfall
placement and underwriting )
Subtract the number of fully paid +ordinary
securities cancelled during that 12 month
period
Nil
“A”
505,336,881
+ See chapter 19 for defined terms.
Appendix 3B Page 10
04/03/2013
Appendix 3B
New issue announcement
Step 2: Calculate 15% of “A”
“B”
0.15
[Note: this value cannot be changed]
Multiply “A” by 0.15
75,800,532
Step 3: Calculate “C”, the amount of placement capacity under rule
7.1 that has already been used
Insert number of +equity securities issued
or agreed to be issued in that 12 month
period not counting those issued:
•
Under an exception in rule 7.2
•
Under rule 7.1A
•
With security holder approval under rule
7.1 or rule 7.4
Note:
• This applies to equity securities, unless
specifically excluded – not just ordinary
securities
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
“C”
3,445,310 FPOs issued on 30 September
2019.
6,000,000 2019 Rights Issue Lead
Manager Listed Options
(exercisable at 0.05 and
exercisable on or before 26
November 2021) issued on 26
November 2019.
2,500,000 FPOs issued on 10 December
2019.
11,945,310
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15
75,800,532
Note: number must be same as shown in
Step 2
Subtract “C”
11,945,310
Note: number must be same as shown in
Step 3
Total [“A” x 0.15] – “C”
63,855,222
[Note: this is the remaining placement
capacity under rule 7.1]
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 11
Appendix 3B
New issue announcement
Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
505,336,881
Note: number must be same as shown in
Step 1 of Part 1
Step 2: Calculate 10% of “A”
“D”
0.10
Note: this value cannot be changed
Multiply “A” by 0.10
50,533,688
Step 3: Calculate “E”, the amount of placement capacity under rule
7.1A that has already been used
Insert number of +equity securities issued
or agreed to be issued in that 12 month
period under rule 7.1A
Nil
Notes:
• This applies to equity securities – not
just ordinary securities
• Include here – if applicable – the
securities the subject of the Appendix
3B to which this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as separate
line items
“E”
Nil
+ See chapter 19 for defined terms.
Appendix 3B Page 12
04/03/2013
Appendix 3B
New issue announcement
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
50,533,688
Note: number must be same as shown in
Step 2
Subtract “E”
Nil
Note: number must be same as shown in
Step 3
Total [“A” x 0.10] – “E”
50,533,688
Note: this is the remaining placement
capacity under rule 7.1A
+ See chapter 19 for defined terms.
04/03/2013
Appendix 3B Page 13
Share your feedback
Discover